Oncology Development Strategies: Considerable Commercial Potential but Specific Needs Must be Addressed

Share Article

This new research report, announced by Research and Markets, provides an in-depth analysis on oncology and the challenges and opportunities for companies in the oncology space.

Research and Markets has announced the addition of the "Oncology Development Strategies: Considerable Commercial Potential but Specific Needs Must be Addressed" report to their offering.

The oncology therapeutic area has seen significant development and advances over the last decade. However, oncology has one of the lowest overall clinical success rates of all therapy areas with only a third of oncology drugs that get to Phase III proceeding to approval. There are a number of factors that will affect the likelihood of success in oncology drug development and these must be taken into consideration when designing the clinical development plan. Oncology clinical trials tend to be more complex than those in other therapy areas, largely due to the number of endpoints that can be utilized, the growing need for adaptive trial design and the types of patients that are eligible for the clinical studies. While overall survival is the gold standard endpoint, achieving this is challenging for many oncology trials and other endpoints such as progression-free survival are frequently used as surrogates.

The approval of oncology drugs has been facilitated by regulatory mechanisms that have been put in place to expedite the process for drugs with small patient populations or that address areas of high unmet need. Programs to allow early access to developmental drugs are becoming the norm in oncology, largely driven by the high unmet need and serious nature of the disease, but also due to a desire to obtain real-life data.

The report, “Oncology Development Strategies - Considerable Commercial Potential but Specific Needs Must Be Addressed”, was written to provide support and guidance to companies who are both new entrants and long time players in the oncology space. CBR Pharma Insights provides in-depth analysis on the challenges that exist in developing new oncology products and launching them successfully into a challenging health care climate.

Key Topics Covered:

Executive summary


Why is oncology different?

Oncology clinical trials

Regulatory strategies

Effective oncology launch strategies

For more information on this report please contact

Research and Markets
Laura Wood, Senior Manager.
Email: press(at)researchandmarkets(dot)com
Tel: +35314151241

Or visit http://www.researchandmarkets.com/research/kpl3k8/oncology

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Laura Wood
Follow us on
Visit website